Revised forecast
Fiscal year ending January 2027 · Cumulative second-quarter periodPrevious forecast published 17 March 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Expenses were lower than initially forecast due to a review of the timing of acceptance inspections for manufacturing-related costs and other factors; some manufacturing costs were recorded as inventories (work in process) following the inclusion of アクーゴ® in the national drug price list and its launch; and foreign exchange gains arose on foreign-currency-denominated loans receivable and related receivables due to the weaker yen.
| Item | Details |
|---|---|
| Operating profit | ¥-2,906 million → ¥-1,909 million |
| Ordinary income | ¥-2,908 million → ¥-1,730 million |
| Profit attributable to owners of the parent | ¥-2,909 million → ¥-1,791 million |
| Net income per share | -37.28 yen and sen → -22.95 yen and sen |
| Fiscal Period Covered | Fiscal year ending January 2027 |
| Period Covered | Cumulative second-quarter period |
| Publication date of previous forecast | 17 March 2026 |
| Previous-period results | Business revenue: Not disclosed, operating loss: ¥1,888 million, ordinary loss: ¥2,481 million, interim net loss attributable to owners of the parent: ¥1,997 million, interim net loss per share: ¥27.80 |
| Reason for the revision | Expenses were lower than initially forecast due to a review of the timing of acceptance inspections for manufacturing-related costs and other factors; some manufacturing costs were recorded as inventories (work in process) following the inclusion of アクーゴ® in the national drug price list and its launch; and foreign exchange gains arose on foreign-currency-denominated loans receivable and related receivables due to the weaker yen. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Expenses were lower than forecast, mainly due to a review of the timing of acceptance inspections for manufacturing-related costs; some manufacturing costs were recorded as inventories following the inclusion of アクーゴ® in the national drug price list and its launch; and foreign exchange gains arose on foreign-currency-denominated loans receivable and other items due to the weaker yen.